Cover Image
市場調查報告書

嬰兒痙攣症 (Infantile spasms) :開發中產品分析

Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 362367
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
嬰兒痙攣症 (Infantile spasms) :開發中產品分析 Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016
出版日期: 2016年12月14日 內容資訊: 英文 63 Pages
簡介

本報告提供嬰兒痙攣症 (Infantile spasms) 治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

嬰兒痙攣症 (Infantile spasms)的概要

治療藥的開發

  • 開發中產品的概要

嬰兒痙攣症 (Infantile spasms):企業開發中的治療藥

嬰兒痙攣症 (Infantile spasms):開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

嬰兒痙攣症 (Infantile spasms):企業開發中的產品

嬰兒痙攣症 (Infantile spasms的)治療藥的開發企業

  • Anavex Life Sciences Corp.
  • Catalyst Pharmaceuticals, Inc.
  • INSYS Therapeutics, Inc.
  • Novartis AG
  • Retrophin Inc.

嬰兒痙攣症 (Infantile spasms):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

嬰兒痙攣症 (Infantile spasms):最近的開發平台趨勢

嬰兒痙攣症 (Infantile spasms):暫停中的計劃

嬰兒痙攣症 (Infantile spasms):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8797IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016, provides an overview of the Infantile Spasm (West Syndrome) (Central Nervous System) pipeline landscape.

Infantile spasms are a type of epilepsy with a characteristic age of onset (typical age when seizures start), pattern of seizures and electroencephalogram (EEG). Symptoms include typical pattern is of a sudden flexion (bending forward) in a tonic (stiffening) fashion of the body, arms and legs. Sometimes, the episodes are different, with the arms and legs being flung outwards (these are called 'extensor' spasms). Causes include central nervous system infections, abnormal brain development or injury, genetic abnormalities (Down syndrome, Miller-Dieker syndrome) and metabolic disorders (mitochondrial diseases, phenylketonuria, and hypoglycemia). Treatment includes antiepileptic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Infantile Spasm (West Syndrome) - Pipeline Review, H2 20164, provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively.Infantile Spasm (West Syndrome).

Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Infantile Spasm (West Syndrome) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Infantile Spasm (West Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Infantile Spasm (West Syndrome) Overview
  • Therapeutics Development
    • Pipeline Products for Infantile Spasm (West Syndrome) - Overview
  • Infantile Spasm (West Syndrome) - Therapeutics under Development by Companies
  • Infantile Spasm (West Syndrome) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Infantile Spasm (West Syndrome) - Products under Development by Companies
  • Infantile Spasm (West Syndrome) - Companies Involved in Therapeutics Development
    • Anavex Life Sciences Corp
    • Catalyst Pharmaceuticals Inc
    • GW Pharmaceuticals Plc
    • INSYS Therapeutics Inc
    • Novartis AG
    • Retrophin Inc
  • Infantile Spasm (West Syndrome) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANAVEX-273 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-5189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cosyntropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cosyntropin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPP-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JBPOS-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Infantile Spasm (West Syndrome) - Dormant Projects
  • Infantile Spasm (West Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 19, 2016: Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports
      • Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
      • Jun 21, 2016: GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
      • May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
      • Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD
      • Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115
      • Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms
      • Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115
      • Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
      • Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia
      • Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome
      • Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference
      • Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry
      • Dec 13, 2011: Catalyst Starts Phase Ia Safety Study For CPP-115
      • Dec 02, 2011: Catalyst To Present Data On CPP-115 At American Epilepsy Society's 65th Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Infantile Spasm (West Syndrome), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Infantile Spasm (West Syndrome) - Pipeline by Anavex Life Sciences Corp, H2 2016
  • Infantile Spasm (West Syndrome) - Pipeline by Catalyst Pharmaceuticals Inc, H2 2016
  • Infantile Spasm (West Syndrome) - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Infantile Spasm (West Syndrome) - Pipeline by INSYS Therapeutics Inc, H2 2016
  • Infantile Spasm (West Syndrome) - Pipeline by Novartis AG, H2 2016
  • Infantile Spasm (West Syndrome) - Pipeline by Retrophin Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Infantile Spasm (West Syndrome) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Infantile Spasm (West Syndrome), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top